Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 09-2022 | 06-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 867,456 | 243,928 | 1,473,138 | 810,674 | 326,053 |
| Depreciation Amortization | 430,013 | 283,914 | 515,698 | 337,437 | 165,110 |
| Accounts receivable | -100,642 | -128,952 | -155,822 | -120,611 | -181,918 |
| Accounts payable and accrued liabilities | -139,385 | -135,274 | 9,944 | -79,998 | -119,783 |
| Other Working Capital | -492,617 | -484,253 | -291,711 | -279,261 | -319,856 |
| Other Operating Activity | 442,144 | 596,642 | 286,712 | 600,163 | 495,149 |
| Operating Cash Flow | $1,006,970 | $376,006 | $1,837,959 | $1,268,403 | $364,755 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -99,324 | -63,410 | -174,539 | -156,857 | -83,411 |
| Net Acquisitions | N/A | N/A | -5,799 | -5,906 | -5,897 |
| Sale Of Investment | 87,149 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -185,198 | -75,876 | -130,082 | -276,476 | -96,096 |
| Other Investing Activity | -237,377 | -83,999 | -238,418 | -344,508 | -102,566 |
| Investing Cash Flow | $-249,552 | $-147,409 | $-418,757 | $-507,270 | $-191,874 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | -108,000 | 115,500 | -352,000 | -364,000 | N/A |
| Common Stock Repurchased | -75,982 | -81,258 | -6,301 | -6,507 | -6,488 |
| Dividend Paid | -328,874 | -351,713 | -750,077 | -354,117 | -354,117 |
| Other Financing Activity | -73,447 | -41,364 | -134,745 | -93,794 | -46,437 |
| Financing Cash Flow | $-586,303 | $-358,835 | $-1,243,123 | $-818,418 | $-407,043 |
| Exchange Rate Effect | 153,511 | 107,346 | 35,869 | -14,005 | 13,868 |
| Beginning Cash Position | 2,275,099 | 2,433,092 | 2,869,927 | 2,967,765 | 2,967,765 |
| End Cash Position | 2,599,726 | 2,410,200 | 3,081,875 | 2,896,485 | 2,747,472 |
| Net Cash Flow | $324,626 | $-22,892 | $211,948 | $-71,289 | $-220,293 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,006,970 | 376,006 | 1,837,959 | 1,268,403 | 364,755 |
| Capital Expenditure | -99,324 | -63,410 | -178,103 | -159,186 | -85,103 |
| Free Cash Flow | 907,646 | 312,597 | 1,659,856 | 1,109,217 | 279,652 |